Monoamine oxidase inhibitors revisited: What you should know

GoldbergJ.F.; ThaseM.E.

首页> 外文期刊>The journal of clinical psychiatry >Monoamine oxidase inhibitors revisited: What you should know

【24h】

Monoamine oxidase inhibitors revisited: What you should know

机译：再谈单胺氧化酶抑制剂：您应该知道的

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Monoamine oxidase inhibitors (MAOIs) have been dubbed the "secret weapon" of psychopharmacology for the treatment of depression.1 While pharmacology futurists await the arrival of so-called "triple reuptake inhibitors" as harbingers of the next generation of antidepressants, MAOIs— which simultaneously enhance serotonergic, noradrenergic, and dopaminergic transmission—have been available for decades. Elegant combination therapies for hard-to-treat depression often aim to increase central activity of all 3 monoamines(suchasbycombiningaserotonin-norepinephrine reuptake inhibitor with a putative dopaminergic drug [eg, bupropion, amphetamine, methylphenidate, or pramipexole] or by pairing a dopamine agonist with a selective serotonin reuptake inhibitor [SSRI] plus a tricyclic antidepressant [TCA]). Or, more simply, one could utilize an MAOI to accomplish analogous pharmacodynamic goals.

机译：单胺氧化酶抑制剂（MAOIs）被称为治疗抑郁症的心理药理学的“秘密武器”。1药理学家们等待着所谓的“三重吸收抑制剂”的到来，它们是下一代抗抑郁药MAOIs的预兆。同时增强5-羟色胺能，去甲肾上腺素能和多巴胺能的传播-已有数十年的历史了。优雅的治疗难治性抑郁症的联合疗法通常旨在提高所有3种单胺的中枢活性（例如通过将色胺酮-去甲肾上腺素再摄取抑制剂与公认的多巴胺能药物[例如安非他酮，苯丙胺，哌醋甲酯或普拉克索]或将多巴胺激动剂与选择性5-羟色胺再摄取抑制剂[SSRI]加三环抗抑郁药[TCA]）。或者，更简单地说，可以利用MAOI完成类似的药效学目标。

著录项

来源
《The journal of clinical psychiatry》 |2013年第2期|共3页
作者
GoldbergJ.F.; ThaseM.E.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类精神病学;
关键词

相似文献

外文文献
中文文献
专利

1. Discovery of a Novel Class of Potent Coumarin Monoamine Oxidase B Inhibitors: Development and Biopharmacological Profiling of 7-[(3-Chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one Methanesulfonate (NW-1772) as a Highly Potent, Selective, Reversible, and Orally Active Monoamine Oxidase B Inhibitor [J] . Pisani L, Muncipinto G, Miscioscia TF, Journal of Medicinal Chemistry . 2009,第21期

机译：一类新型强力香豆素单胺氧化酶B抑制剂的发现：7-[（3-氯苄基）氧基] -4-[（甲基氨基）甲基] -2H-铬-2-酮甲烷磺酸盐（NW-1772）的开发和生物药理学分析）作为高效，选择性，可逆和口服活性单胺氧化酶B抑制剂
2. Monoamine Oxidase Inhibitors—Revisiting a Therapeutic Principle [J] . Michael Entzeroth, Anil K. Ratty Open Journal of Depression . 2017,第2期

机译：单胺氧化酶抑制剂 - 重新审视治疗原则
3. Revisiting the Role of Monoamine Oxidase Inhibitors in Pediatric Psychopharmacology [J] . Pumariega Andres J., Pradhan Basant K. Psychiatric annals . 2014,第11期

机译：复习单胺氧化酶抑制剂在儿科心理药理学中的作用
4. Quantitative Structure Activity Relationship of New 7-Oxycoumarin Derivatives As Potent and Selective Monoamine Oxidase A Inhibitors [C] . Xianchao Li, Hongzong Si, Hua Gao International Forum on Materials Science and Industrial Technology . 2013

机译：新的7-Oxycoumarin衍生物作为有效和选择性单胺氧化酶氧化酶的定量结构活性关系
5. Influence of Monoamine Oxidase Inhibitors on Nicotine Self-Administration. [D] . Arnold, Monica Martin. 2011

机译：单胺氧化酶抑制剂对尼古丁自我管理的影响。
6. Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone and assessment of their effect on psychometric performance in healthy subjects. [O] . I Berlin, R Zimmer, H M Thiede, 1990

机译：两种可逆和选择性单胺氧化酶-A抑制剂莫洛贝米德和托洛沙酮的单胺氧化酶抑制特性的比较并评估它们对健康受试者心理测量的影响。
7. Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects. [O] . Berlin, I, Zimmer, R, Thiede, H M, 1990

机译：两种可逆和选择性单胺氧化酶-A抑制剂莫洛贝米德和托洛沙酮的单胺氧化酶抑制特性的比较，并评估它们对健康受试者心理测量的影响。

Monoamine oxidase inhibitors revisited: What you should know

摘要

著录项

相似文献

相关主题

期刊订阅